Newsletter

Pol. Merkur. Lek (Pol. Med. J.), 2013, XXXIV/201: 161-164 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2013, XXXIV/201: 161-164

Title: Variety of thrombotic thrombocytopenic purpura clinical course in Polish family members with ADAMTS 13 gene mutation

Authors: Hyla-Klekot L., Kucharska G., Słonka K

More details

07/201

40,00 zł

SUMMARY IN POLISH & ENGLISH. FULL ARTICLE ONLY IN POLISH.

Variety of thrombotic thrombocytopenic purpura clinical course in Polish family members with ADAMTS 13 gene mutation


Hyla-Klekot L.1,2, Kucharska G.1, Słonka K.2

1Centrum of Paediatry and Oncology in Chorzow, Poland; 2Technical University of Opole, Poland; Institute of Physiotherapy, Faculty of Physical Education and Physiotherapy

The congenital form of thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrom) is a result of genetically conditioned dysfunction of protease ADAMTS 13 enzyme which is responsible for von Wiellebrand factor multimer disintegration. The disease is inherited autosomally and recessively. The decrease of ADAMTS 13 activity results in intravascular clotting process activation with rapid lowering of platelet count, haemolytic anaemia, and occurence of schistocytes. Clinically, the disease is characterized by a range of symptoms such as severe jaundice in neonatal period, embolicthrombotic incidents of nervous system and progressive dysfunction of kidneys and other organs. Delaying diagnosis and hence administering of freshly frozen plasma leads to death. Molecular diagnosis allows for identification of genetical profile of the patient, and showing lowered enzyme activity is a basis for regular prophylactic plasma administration which is the protease donor. In our study we present members of a Polish family identified with ADAMTS 13 mutation. 52 old male with heterozygotic mutation of exon 29 (4143_4144insA) and in exon 19 (c2281G>A; Gly761Ser), experienced a few episodes of ischaemic stroke with ongoing neurological deficiency and developed chronic kidney disease. His 16-year old daughter with double homozygotic mutation in exon 29 (4143_4144insA) after severe episode of TTP at the age of 4 has been receiving plasma every 2 weeks for 12 years, which prevented her from other disorders. Target treatment introduced to clinical practice by means of ADAMTS 13 obtained by genetic recombination technology raises hopes.

Key words: thrombotic thrombocytopenic purpura, Upshaw-Schulman syndrom, protease ADAMTS 13, thrombocytopenia, chronic kidney disease

Pol. Merk. Lek., 2013, XXXIV, 201, 161